Filtered By:
Specialty: Pharma Commentators

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 48 results found since Jan 2013.

Tamiflu saga continues - NYT. By Katie Thomas
Breaking the Seal on Drug ResearchPETER DOSHI walked across the campus of Johns Hopkins University in a rumpled polo shirt and stonewashed jeans, a backpack slung over one shoulder. An unremarkable presence on a campus filled with backpack-toters, he is 32, and not sure where he’ll be working come August, when his postdoctoral fellowship ends. And yet, even without a medical degree, he is one of the most influential voices in medical research today.Dr. Doshi’s renown comes not from solving the puzzles of cancer or discovering the next blockbuster drug, but from pushing the world’s biggest pharmaceutical companie...
Source: PharmaGossip - June 30, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs

Experts Propose Restoring Invisible And Abandoned Trials 'To Correct The Scientific Record'
Main Category: Clinical Trials / Drug TrialsAlso Included In: Pharma Industry / Biotech Industry;  Public HealthArticle Date: 13 Jun 2013 - 18:00 PDTCurrent ratings for:Experts Propose Restoring Invisible And Abandoned Trials 'To Correct The Scientific Record'Patient / Public:Healthcare Prof:Group calls for authors and participating journals to join the effort Analysis: Restoring invisible and abandoned trials: a call for people to publish the findingsEditorial: Restoring the integrity of the clinical trial evidence base Experts are today calling for all unpublished and misreported trials to b...
Source: PharmaGossip - June 14, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs

Pharmalot... Pharmalittle... Good Morning
Rise and shine, everyone, another day has arrived. Not only that, but the rain has stopped, at least for now. Whatever the weather forecast might say, though, our spirits remain sunny. As the Morning Mayor taught us long ago: 'Every brand new day should be unwrapped like a precious gift.' So while you tug on the ribbon, we will reach for the mandatory cup of stimulation and get on with foraging for interesting developments. Meanwhile, here are a few tidbits. Have a grand day and thanks to all for providing some useful tips lately... AstraZeneca And Takeda To Bid On Israeli Biotech Incubator (Globes) FDA Approves Sanofi Fou...
Source: Pharmalot - June 11, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs

Bringing trial data out of the shadows
All sectors have their own mood music, unobtrusive much of the time, but occasionally brought to startling effect into the foreground, dominating all else. The pharmaceutical industry is no different, and at present there is one insistent theme: transparency.And if there is one area of this debate behind which chords are starting to swell loudly it is the availability of clinical trial data. Unflattering or disappointing trial outcomes have been routinely unpublished, pharma's critics claim, which means patients taking part in trials can be exposed to ineffective or even dangerous products because previous negative researc...
Source: PharmaGossip - May 13, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs

Fixing Pharma's Reputation: IMHO, the Train Has Left the Station
In an "open letter" to PhRMA CEO, John Castellani, Forbes Blogger and former president of Pfizer Global Research, John LaMattina, offers several suggestions for improving the reputation of the pharmaceutical industry. You can read the "letter" here.Unfortunately, IMHO, the "train has already left the station" as they say. In fact, the train has crashed!You might recall that LaMattina famously called for the end of DTC (direct-to-consumer) advertising in his book, Devalued and Distrusted (see "Bad, Devalued, Distrusted & Defensive Pharma: A Tale of Two Books").In his open letter, however, LaMattina focuses on the R&...
Source: Pharma Marketing Blog - April 21, 2013 Category: Pharma Commentators Tags: R and D Research Sales and Sales Reps Reputation Source Type: blogs

Half of Tamiflu prescriptions went unused during 2009 swine flu pandemic
Around 50% of the Tamiflu prescriptions issued during the influenza pandemic in 2009–10 went unused in England, a study by the UK’s Centre for Ecology & Hydrology (CEH) has found. The unused medication represents approximately 600,000 courses of Tamiflu at a cost of around £7.8m to the UK taxpayer. The finding, published online in the open access scientific journal Plos One, comes from the first study of its kind to use sewage water to estimate drug compliance rates. The study estimated usage of pharmaceuticals from large populations by sampling sewage and recovering the active component of Tamiflu, thus measuring d...
Source: PharmaGossip - April 17, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs

The Myth of Tamiflu: 5 Things You Should Know - by Harlan Krumholz
Influenza-like-illness is sweeping the country with the Centers for Disease Control & Prevention reporting that most areas of the country experiencing high rates. I should know, my family is in the midst of it despite having been vaccinated. This year may rival some of the worst years in recent history. These illnesses are more than uncomfortable – they can cause life-threatening complications. Worries about complications lead many people to want to be prepared with a treatment. I have a friend who once stockpiled Tamiflu, an antiviral agent sold by Roche, wanting to be prepared to protect his friends and family. He was...
Source: PharmaGossip - April 13, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs

A Mobile App for Crowdsourcing Vaccine Refusal Data: A Model for Improving Drug Adherence
A mobile app for tracking vaccination refusal was recently released by the University of Iowa Computational Epidemiology Group. It's called simply "vaccine refused." According to the developers, "vaccinations are one of the most important interventions for preventing the spread of several infectious diseases. Refusing recommended vaccinations puts communities at greater risk for outbreaks of vaccine preventable diseases. This app enables pediatricians and other health care providers to very quickly document and track instances of vaccine refusal."I downloaded the app and used it even though I am NOT a healthcare provider. ...
Source: Pharma Marketing Blog - April 10, 2013 Category: Pharma Commentators Tags: Vaccine Apps Mobile Adherence Source Type: blogs

Pharmalot... Pharmalittle... Good Morning
Hello, everyone, and nice to see you again. Once again, we apologize for the recent inability to access the site. As you might imagine, we have not been happy either with the way the redesign was handled, but we are moving forward, as always, and quaffing another cup of stimulation to help us along. Please join us. After all, there is much to do. With that said, here are some tidbits to get you started. Meanwhile, thanks for your patience and please do stay in touch, especially if you hear something interesting... China Reports Its Eight Bird Flu Death (Reuters) Pfizer R&D Building Demolition May Be Delayed (The Day...
Source: Pharmalot - April 9, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs

Roche offers researchers access to all Tamiflu trials
BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f2157 (Published 4 April 2013) Cite this as: BMJ 2013;346:f2157 Article Related content Article metrics Deborah Cohen Author Affiliations More than three years after the Cochrane Collaboration first asked Roche for the full clinical study reports for its influenza drug oseltamivir (Tamiflu), the Swiss company has offered the collaboration access to “all 74 Roche sponsored trials.” Don MacLean, life cycle leader for Tamiflu at Roche, emailed the Cochrane researchers on 2 April to propose providing d...
Source: PharmaGossip - April 4, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs

A Fight Over Antibiotics In Food-Producing Animals
As a US Senate committee holds a hearing today on renewing the Animal Drug User Fee Act, a coalition of three dozen advocacy groups is urging committee members to strengthen the law so that antibiotics given food-producing livestock do not create human resistance to the medicines. The effort comes just as two members of Congress introduced a bill to require better data on the use of antibiotics given to animals raised for human consumption. At issue is inappropriate or overuse of antibiotics, which advocates argue is contributing to a public health crisis. They contend the FDA should increase its oversight, which last summ...
Source: Pharmalot - February 27, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Antibiotic Resistance Antibiotics Eli Lilly Merck Pew Charitbale Trusts Pfizer Source Type: blogs

Pharmalot… Pharmalittle… Good Morning
Good morning, folks, and how are you today? A spot of rain is falling on the Pharmalot corporate campus, where we are doing our best to energize the short people and tend to the usual early-in-the-day to-do list. Of course, the middle of the week only intensifies the need to move quickly. We trust you relate. So join us as we grab another cup of stimulation and dig in for another busy day. As always, here are some items of interest to help you along. Hope your day is smashing and do stay in touch… FDA OKs Pill For Post-Menopausal Sex Problems (Los Angeles Times) Allergan Settles Oklahoma Botox Case During Trial (Bloo...
Source: Pharmalot - February 27, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Allergan AstraZeneca Biosimilars Botox Cystic Fibrosis Elan FDA Flu GlaxoSmithKline Hospira Influenza Menopause Merck Narcolepsy Osphena Pandemrix Royalty Pharma SFDA Shionogi Tredaptive Vertex Pharm Source Type: blogs

Which bit of All and Trials don't Roche understand?
Drug firm Roche pledges greater access to trials data 26 February 2013 Last updated at 18:00 Research suggests half of all clinical trials have never been published The pharmaceutical company Roche has announced that it will make more of the data from its clinical trials available to researchers. The company says it will appoint a panel of experts to evaluate and approve requests to access anonymised patient data. We understand and support calls for our industry to be more transparent” Daniel O'Day Roche But the announcement has been dismissed as "pathetic" by campaigners arguing for greater transparency from the ph...
Source: PharmaGossip - February 27, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs